Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies Directed to GPNMB and Uses Thereof

a technology of gpnmb and antibodies, applied in the field of antibodies with specificity to gpnmb, can solve the problems of loss or addition of residues at the junction, approach, short half-life in vivo, and inefficient effector functions

Inactive Publication Date: 2015-02-12
AMGEN FREMONT INC +1
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides human monoclonal antibodies that specifically bind to GPNMB, as well as variants, derivatives, and antigen-binding fragments of these antibodies. These antibodies can neutralize the activity of GPNMB and are cross-reactive with other fully human anti-GPNMB antibodies. The invention also provides naked IgG1 anti-GPNMB antibodies that have cytotoxic effects on cells overexpressing GPNMB, as well as immunomodulators and immunoconjugates comprising anti-GPNMB antibodies and cytotoxic agents for treating GPNMB-related disorders. The invention also provides amino acid sequences and nucleic acid sequences encoding the anti-GPNMB human monoclonal antibodies.

Problems solved by technology

The joining of V, C and J regions can result in the loss or addition of residues at the junctions.
The approach, which initially utilized mouse monoclonal antibodies has encountered limitations to potential effectiveness such as immunogenicity; inefficient effector functions and short half-life in vivo.
One of the challenges in developing biAbs as viable therapeutics has been producing large enough quantities of a stable moiety for clinical applications.
Another challenge has been in determining the right combination of validated targets and the underlying biology that would lead to a therapeutic product.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies Directed to GPNMB and Uses Thereof
  • Antibodies Directed to GPNMB and Uses Thereof
  • Antibodies Directed to GPNMB and Uses Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Immunogen

[0233]Recombinant human GPNMB (SEQ ID NO:289), specifically the extra-cellular domain (ECD) was prepared for use as the immunogen. Generally, cDNA encoding the ECD of GPNMB with a C-terminus V5-HIS tag was transfected into HEK 293 cells, expressed and purified using cation exchange chromatography with a POROS HS 50 (Applied Biosystems, Foster City, Calif.). Sample was eluted with 1M NaCl at a pH of 5.5, followed by metal affinity chromatography (Pharmacia metal chelate 5 mL). The sample was eluted against a linear gradient from 10-500 mM imidazole over 10 CV (column volumn). Dialysis occurred using 20 mM Tris / 50 mM NaCl at pH 7.4 (2 L×2). The sample was then filtered through a 0.22 μm filter.

example 2

Immunization

[0234]A preferred method for generating fully human antibodies uses XenoMouse® strains of mice which have been engineered to contain 245 kb and 190 kb-sized germline configuration fragments of the human heavy chain locus and kappa light chain locus (Green et al. 1994 Nature Genetics 7:13-21; Mendez et al. 1997 Nature Genetics 15:146-156; Green and Jakobovits, 1998 J. Exp. Med. 188:483-495; U.S. Pat. Nos. 6,162,963, 6,150,584, 6,114,598, 6,075,181, and 5,939,598). In an alternative approach, the minilocus approach, an exogenous Ig locus is mimicked through the inclusion of pieces (individual genes) from the Ig locus. Thus, one or more VH genes, one or more DH genes, one or more JH genes, a mu constant region, and a second constant region (preferably a gamma constant region) are formed into a construct for insertion into an animal (Taylor et al., 1992, Chen et al., 1993, Tuaillon et al., 1993, Choi et al., 1993, Lonberg et al., (1994), Taylor et al., (1994), and Tuaillon e...

example 3

Antibodies

[0243]Hybridoma cell lines were generated from immunized mice demonstrated to have anti-GPNMB titers using standard techniques (see Mendez et al, 1997, Nat. Genet. 15:146-156).

[0244]Immunized mice were sacrificed by cervical dislocation, and the lymph nodes were harvested and pooled from each cohort. The lymphoid cells were dissociated by grinding in DMEM to release the cells from the tissues, and the cells were suspended in DMEM. The cells were counted, and 0.9 mL DMEM per 100 million lymphocytes was added to the cell pellet to resuspend the cells gently but completely. Using 100 μl of CD90+ magnetic beads per 100 million cells, the cells were labeled by incubating the cells with the magnetic beads at 4° C. for 15 minutes. The magnetically-labeled cell suspension containing up to 108 positive cells (or up to 2×109 total cells) was loaded onto a LS+ column and the column washed with DMEM. The total effluent was collected as the CD90-negative fraction (most of these cells w...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides fully human monoclonal antibodies that specifically bind to GPNMB, and uses thereof. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and / or complementarity determining regions (CDRs) are provided. The present invention also provides immunoconjugates comprising anti-GPNMB antibodies and methods of using such immunoconjugates. The present invention further provides bi-specific antibodies comprising an anti-GPNMB antibody component and an anti-CD3 component, and methods of using such bispecific antibodies.

Description

RELATED APPLICATIONS[0001]This application is a continuation of U.S. patent application Ser. No. 13 / 355,366, filed Jan. 20, 2012, which is a continuation of U.S. patent application Ser. No. 13 / 151,690, filed Jun. 2, 2011, which is a continuation of U.S. patent application Ser. No. 12 / 911,269, filed Oct. 25, 2010, which is a continuation of U.S. patent application Ser. No. 12 / 721,099, filed Mar. 10, 2010, which is a continuation of U.S. patent application Ser. No. 12 / 506,029, field Jul. 20, 2009, which is a continuation of U.S. patent application Ser. No. 12 / 290,779, filed Nov. 3, 2008, which is a continuation of U.S. patent application Ser. No. 11 / 792,032, which is a national stage application, filed under 35 U.S.C. §371, of International Application No. PCT / US2005 / 043482, filed on Nov. 30, 2005, which claims priority to U.S. Provisional Application No. 60 / 632,023, filed Nov. 30, 2004, and U.S. Provisional Application No. 60 / 733,779, filed Nov. 7, 2005; the contents of each of which...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K16/30C07K16/28A61K47/48
CPCC07K16/3053A61K47/48623A61K47/48438C07K16/2809C07K16/3061A61K47/4863C07K2317/622C07K2317/62C07K2317/565A61K2039/505C07K2317/31C07K2317/73C07K2317/21A61K2039/545C07K16/30C07K2317/732C07K2317/77C07K2317/94A61K47/6849A61K47/6851A61P25/00A61P35/00A61P43/00A61K47/68031A61K47/6803
Inventor XIAO, FENGJIA, XIAO-CHILIANG, MEINAFOORD, ORITKLAKAMP, SCOTTTSE, KAM FAIPOLLACK, VINCENT A.RASTELLI, LUCAHERRMANN, JOHNLICHENSTEIN, HENRIJEFFERS, MICHAEL E.LAROCHELLE, WILLIAM J.ARA, GULSHANMEZES, PETERCHAPOVAL, ANDREIKARKARIA, CYRUSTORGOV, MICHAELDAVAGNINO, JUAN
Owner AMGEN FREMONT INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com